why choose us

First received: October 10, 2025

Clinical Trial: WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Obesity & Overweight

Study Type: OBSERVATIONAL


Official Title: WeDosify Real-World Evidence: Evaluating a Clinical Decision Support and Patient Engagement Tool for Personalized Semaglutide Dosing in Adults With Overweight or Obesity in the United States

Brief Summary: This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.

Read more